OPEN SOURCE AUTOMATED INSULIN DELIVERY SYSTEMS: BENEFITS, LIMITATIONS AND CHALLENGES IN DIABETES CARE

被引:2
|
作者
Shishin, Konstantin S. [1 ,2 ]
Klimontov, Vadim V. [1 ]
机构
[1] Russian Acad Sci, Siberian Branch, Branch Inst Cytol & Genet, Res Inst Clin & Expt Lymphol, Novosibirsk, Russia
[2] Novosibirsk Natl Res State Univ, Novosibirsk, Russia
来源
DIABETES MELLITUS | 2023年 / 26卷 / 04期
关键词
diabetes; automated insulin delivery; insulin delivery system; artificial pancreas; closed loop; open source; continuous glucose monitoring; ARTIFICIAL PANCREAS;
D O I
10.14341/DM13022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Open source closed loop automated insulin delivery (CL-AID) systems are increasingly used in the treatment of diabetes. Assembled on a do-it-yourself (DIY) basis, these systems integrate insulin pumps, continuous glucose monitoring devices, and algorithms that control the rate of insulin delivery based on glucose levels. In this review, we consider the technological features of open source CL-AID systems (OpenAPS, AndroidAPS, Loop, etc.), advantages and barriers to their use in clinical practice. Advantages of open source CL-AID systems over commercially available ones included lower cost, a choice of devices, a wide range of user settings, as well as continuous improvement of algorithms. A growing body of evidence indicates that open source CL-AID systems, such as OpenAPS, AndroidAPS, and Loop, provide an excellent time in range with minimal risk of hypoglycaemia and increase treatment satisfaction in patients with type 1 diabetes. A wide range of settings makes open source systems an effective tool for managing diabetes in situations with rapidly changing insulin requirement. However, some technological, medical, legal and ethical issues associated with the use of non-commercial CL-AID systems still need to be addressed. Assembling the system requires skills in diabetes technology. The issue of cybersecurity is also relevant. Lack of official approvals, low awareness of medical professionals, and reimbursement issues are slowing down the introduction of the technology into clinical practice. The professional medical community at the international and national levels needs to determine its position regarding the use of open source CL-AID systems in the treatment of diabetes.
引用
收藏
页码:352 / 362
页数:11
相关论文
共 50 条
  • [21] GLYCEMIC OUTCOMES WITH OPEN-SOURCE AUTOMATED INSULIN DELIVERY SYSTEMS AFTER 12 MONTHS OF USE IN ADULTS WITH TYPE 1 DIABETES
    Amuedo-Dominguez, S.
    Ramirez-Belmar, M.
    Antequera-Gonzalez, M.
    Rodriguez-Acebron, N.
    Tafur-Garcia, L.
    Gomez-Gimenez, F.
    Soto-Moreno, A.
    Azriel-Mira, S.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A110 - A111
  • [22] Open-source automated insulin delivery systems and formal healthcare: A qualitative study of challenges in the interaction between service-users with type 1 diabetes and healthcare professionals
    Raimond, Linda H.
    O'Donnell, Shane
    Boggild-Damkvist, Tobias
    Filges, Tine
    Lomborg, Kirsten
    CHRONIC ILLNESS, 2023, 19 (04) : 836 - 847
  • [23] International Consensus on the Ethics of Open-Source Automated Insulin Delivery
    Braune, Katarina
    Hussain, Syed Sufyan
    Quigley, Muireann
    Petruzelkova, Lenka
    Scheiner, Gary
    Winterdijk, Per
    Schmidt, Signe
    Raimond, Linda H.
    Hood, Korey K.
    Riddell, Michael
    Skinner, Timothy C.
    Raile, Klemens
    Johnston, Carolyn
    Lal, Rayhan
    DIABETES, 2021, 70
  • [24] Automated insulin delivery systems: from early research to routine care of type 1 diabetes
    Eric Renard
    Acta Diabetologica, 2023, 60 : 151 - 161
  • [26] Recommendations for Diabetes-Treatment with systems for Automated Insulin Delivery
    von dem Berge, Thekla
    Biester, Sarah
    Biester, Torben
    Buchmann, Anne-Kathrin
    Datz, Nicolin
    Grosser, Ute
    Kapitzke, Kerstin
    Klusmeier, Britta
    Remus, Kerstin
    Reschke, Felix
    Tiedemann, Inken
    Weiskorn, Jantje
    Wursig, Martina
    Thomas, Andreas
    Kordonouri, Olga
    Danne, Thomas
    DIABETOLOGIE UND STOFFWECHSEL, 2022, 17 (01) : 61 - 73
  • [27] Challenges of Diabetes Care and Insulin Delivery in Nursing Home Facilities
    Spratt, Susan E.
    Mabrey, Melanie E.
    White, Heidi
    Pavlis, Bernadette
    Hyland, Kristen
    Kelley, Carly
    Twersky, Jack
    DIABETES, 2014, 63 : A345 - A345
  • [28] Psychosocial Outcomes Among Users and Nonusers of Open-Source Automated Insulin Delivery Systems: Multinational Survey of Adults With Type 1 Diabetes
    Schipp, Jasmine
    Hendrieckx, Christel
    Braune, Katarina
    Knoll, Christine
    O'Donnell, Shane
    Ballhausen, Hanne
    Cleal, Bryan
    Waeldchen, Mandy
    Lewis, Dana M.
    Gajewska, Katarzyna A.
    Skinner, Timothy C.
    Speight, Jane
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2023, 25
  • [29] Comparison of Control-IQ and open-source AndroidAPS automated insulin delivery systems in adults with type 1 diabetes: The CODIAC study
    Do, Quoc Dat
    Haskova, Aneta
    Radovnicka, Lucie
    Konecna, Judita
    Horova, Eva
    Parkin, Christopher G.
    Grunberger, George
    Prazny, Martin
    Soupal, Jan
    DIABETES OBESITY & METABOLISM, 2024, 26 (01): : 78 - 84
  • [30] Assessment of Risks and Benefits of Beta Cell Replacement Versus Automated Insulin Delivery Systems for Type 1 Diabetes
    Peter Senior
    Anna Lam
    Kate Farnsworth
    Bruce Perkins
    Remi Rabasa-Lhoret
    Current Diabetes Reports, 2020, 20